Quarterly ResultMay 5, 2026, 04:15 PM
Supernus Q1 Total Revenue $207.7M, up 39%
AI Summary
Supernus Pharmaceuticals reported strong first quarter 2026 financial results, with total revenues increasing 39% year-over-year to $207.7 million. The combined revenues from its four growth products surged 56% to $149.1 million, driven by strong sales of Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. The company reiterated its full year 2026 financial guidance and provided updates on its pipeline, including an expected regulatory submission for a second ONAPGO supplier in Q3 2026.
Key Highlights
- Total revenues were $207.7 million in Q1 2026, a 39% increase year-over-year.
- Combined revenues from growth products increased 56% to $149.1 million in Q1 2026.
- ONAPGO net product sales reached $8.4 million in the first quarter of 2026.
- Collaboration revenue from ZURZUVAE was $27.6 million in Q1 2026.
- Qelbree net sales increased 20% to $77.9 million in Q1 2026.
- GOCOVRI net sales increased 15% to $35.2 million in Q1 2026.
- Operating loss improved to $8.3 million in Q1 2026 from $10.3 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $384.2 million as of March 31, 2026.
Price Impact
More from SUPN